Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer
August 08, 2018 08:30 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food...
Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent
April 11, 2017 07:30 ET
|
Intellia Therapeutics, Inc.
Patent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeuticsPatent covers compositions of CRISPR single guide RNA technology for use in non-cellular and...